Audentes Therapeutics to Participate in Upcoming Investor Conferences - Aug. 26, 2019

August 26, 2019 |

1 min read

Audentes Therapeutics, Inc. announced that it will participate in the following investor conferences in September

SAN FRANCISCO, Aug. 26, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced that it will participate in the following investor conferences in September:

Citi’s 14th Annual Biotech Conference
Matthew R. Patterson, Chariman and Chief Executive Officer
Format: 1x1 Investor Meetings
Wednesday, September 4, 2019 - Thursday, September 5, 2019
Boston, Massachusetts

Morgan Stanley 17th Annual Global Healthcare Conference
Natalie Holles, President and Chief Operating Officer
Format: Fireside Chat
Monday, September 9, 2019, at 11:05 am ET
New York, New York

To access the live webcast of the Morgan Stanley fireside chat, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. Following the conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days.

About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases. We are leveraging our AAV gene therapy technology platform and proprietary manufacturing expertise to develop programs across three modalities: gene replacement, vectorized exon skipping, and vectorized RNA knockdown. Our product candidates are showing promising therapeutic profiles in clinical and preclinical studies across a range of neuromuscular diseases. Audentes is a focused, experienced and passionate team driven by the goal of improving the lives of patients.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com

Media Contact:
Sarah Spencer
415.957.2020
sspencer@audentestx.com

Audentes Therapeutics, Inc. (PRNewsfoto/Audentes Therapeutics, Inc.)